Coverage
-
October 29, 2018
A North Carolina judge on Friday dismissed a putative class action accusing drugmaker Cempra Inc. of failing to disclose significant risks associated with an experimental antibiotic used to treat pneumonia, finding the complaint's allegations did not raise the inference that Cempra or its officers intended to mislead investors.
2 other articles on this case.
View all »